Clinical Trials

* Key Common Inclusion Criteria for Parts 1 and 2:

* Patients who are ≥ 18 years old at the time of informed consent
* Patients who have disease measurable by RECIST v1.1
* Patients with an ECOG PS of 0 or 1
* Patients with a life expectancy of at least 3 months in the judgement of the investigator or subinvestigator
* The specified periods have passed respectively after the completion of previous cancer treatments as of the date of enrollment
* Patients who agree to use a medically effective method of contraception
* Key Additional Inclusion Criterion for Part 1:

?Patients with histological or cytological evidence of at least one locally advanced or metastatic non-CNS solid tumor
* Key Additional Inclusion Criteria for Part 2:

* Patients with histological or cytological evidence of any of the following disease:
* Gastric adenocarcinoma, GEJ adenocarcinoma, or esophageal adenocarcinoma
* NSCLC
* Patients who are suitable for docetaxel treatment
* Key Common Exclusion Criteria for Parts 1 and 2:

* Patients with an uncontrolled or serious intercurrent illness
* Patients with known active central nervous system metastasis
* Patients with a history of ≥ Grade 3 allergic reaction to any antibody drug
* Patients with a history of autoimmune disease
* Patients with a history of HIV, HBV, or HCV at screening
* Patients who have a history of primary immunodeficiency
* Key Additional Exclusion Criterion For Part 2:

* Patients with a history of treatment with docetaxel

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/17/2024. Questions regarding updates should be directed to the study team contact.